214 related articles for article (PubMed ID: 35145077)
41. Biology and bioinformatics of myeloma cell.
Abroun S; Saki N; Fakher R; Asghari F
Lab Hematol; 2012 Dec; 18(4):30-41. PubMed ID: 23253865
[TBL] [Abstract][Full Text] [Related]
42. Contact of myeloma cells induces a characteristic transcriptome signature in skeletal precursor cells -Implications for myeloma bone disease.
Dotterweich J; Schlegelmilch K; Keller A; Geyer B; Schneider D; Zeck S; Tower RJ; Ebert R; Jakob F; Schütze N
Bone; 2016 Dec; 93():155-166. PubMed ID: 27519972
[TBL] [Abstract][Full Text] [Related]
43. Co-evolution of tumor and immune cells during progression of multiple myeloma.
Liu R; Gao Q; Foltz SM; Fowles JS; Yao L; Wang JT; Cao S; Sun H; Wendl MC; Sethuraman S; Weerasinghe A; Rettig MP; Storrs EP; Yoon CJ; Wyczalkowski MA; McMichael JF; Kohnen DR; King J; Goldsmith SR; O'Neal J; Fulton RS; Fronick CC; Ley TJ; Jayasinghe RG; Fiala MA; Oh ST; DiPersio JF; Vij R; Ding L
Nat Commun; 2021 May; 12(1):2559. PubMed ID: 33963182
[TBL] [Abstract][Full Text] [Related]
44. PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression.
Mussetti A; Pellegrinelli A; Cieri N; Garzone G; Dominoni F; Cabras A; Montefusco V
Ann Hematol; 2019 Jul; 98(7):1713-1720. PubMed ID: 31053880
[TBL] [Abstract][Full Text] [Related]
45. From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells.
van Nieuwenhuijzen N; Spaan I; Raymakers R; Peperzak V
Cancer Res; 2018 May; 78(10):2449-2456. PubMed ID: 29703720
[TBL] [Abstract][Full Text] [Related]
46. Decorin is down-regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF-induced myeloma plasma cell viability and migration.
Kristensen IB; Pedersen L; Rø TB; Christensen JH; Lyng MB; Rasmussen LM; Ditzel HJ; Børset M; Abildgaard N
Eur J Haematol; 2013 Sep; 91(3):196-200. PubMed ID: 23607294
[TBL] [Abstract][Full Text] [Related]
47. Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche.
Colombo M; Galletti S; Bulfamante G; Falleni M; Tosi D; Todoerti K; Lazzari E; Crews LA; Jamieson CH; Ravaioli S; Baccianti F; Garavelli S; Platonova N; Neri A; Chiaramonte R
Oncotarget; 2016 Aug; 7(35):56013-56029. PubMed ID: 27463014
[TBL] [Abstract][Full Text] [Related]
48. Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma.
Iannozzi NT; Marchica V; Toscani D; Burroughs Garcìa J; Giuliani N; Storti P
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555090
[TBL] [Abstract][Full Text] [Related]
49. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.
Vij R; Mazumder A; Klinger M; O'Dea D; Paasch J; Martin T; Weng L; Park J; Fiala M; Faham M; Wolf J
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):131-139.e1. PubMed ID: 24629890
[TBL] [Abstract][Full Text] [Related]
50. A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma.
Boylan KL; Gosse MA; Staggs SE; Janz S; Grindle S; Kansas GS; Van Ness BG
Cancer Res; 2007 May; 67(9):4069-78. PubMed ID: 17483317
[TBL] [Abstract][Full Text] [Related]
51. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
[TBL] [Abstract][Full Text] [Related]
52. Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.
Wang J; Faict S; Maes K; De Bruyne E; Van Valckenborgh E; Schots R; Vanderkerken K; Menu E
Oncotarget; 2016 Jun; 7(25):38927-38945. PubMed ID: 26950273
[TBL] [Abstract][Full Text] [Related]
53. Tumor-host cell interactions in the bone disease of myeloma.
Fowler JA; Edwards CM; Croucher PI
Bone; 2011 Jan; 48(1):121-8. PubMed ID: 20615487
[TBL] [Abstract][Full Text] [Related]
54. FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma.
Zhang W; Wu C; Geng S; Wang J; Yan C; Zhang X; Zhang JJ; Wu F; Pang Y; Zhong Y; Wang J; Fu W; Huang X; Wang W; Lyu X; Huang Y; Jing H
Aging (Albany NY); 2023 May; 15(9):3644-3677. PubMed ID: 37155154
[TBL] [Abstract][Full Text] [Related]
55. Immunohistochemical evaluation of 95 bone marrow reactive plasmacytoses.
Ioannou MG; Stathakis E; Lazaris AC; Papathomas T; Tsiambas E; Koukoulis GK
Pathol Oncol Res; 2009 Mar; 15(1):25-9. PubMed ID: 18553158
[TBL] [Abstract][Full Text] [Related]
56. Structural and Ultrastructural Analysis of the Multiple Myeloma Cell Niche and a Patient-Specific Model of Plasma Cell Dysfunction.
Harmon KA; Roman S; Lancaster HD; Chowhury S; Cull E; Goodwin RL; Arce S; Fanning S
Microsc Microanal; 2022 Feb; 28(1):254-264. PubMed ID: 34881690
[TBL] [Abstract][Full Text] [Related]
57. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states.
Rasche L; Schinke C; Maura F; Bauer MA; Ashby C; Deshpande S; Poos AM; Zangari M; Thanendrarajan S; Davies FE; Walker BA; Barlogie B; Landgren O; Morgan GJ; van Rhee F; Weinhold N
Nat Commun; 2022 Aug; 13(1):4517. PubMed ID: 35922426
[TBL] [Abstract][Full Text] [Related]
58. Increased expression of metalloproteinase-2 and -9 (MMP-2, MMP-9), tissue inhibitor of metalloproteinase-1 and -2 (TIMP-1, TIMP-2), and EMMPRIN (CD147) in multiple myeloma.
Urbaniak-Kujda D; Kapelko-Slowik K; Prajs I; Dybko J; Wolowiec D; Biernat M; Slowik M; Kuliczkowski K
Hematology; 2016 Jan; 21(1):26-33. PubMed ID: 26268417
[TBL] [Abstract][Full Text] [Related]
59. Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma.
Laganà A; Perumal D; Melnekoff D; Readhead B; Kidd BA; Leshchenko V; Kuo PY; Keats J; DeRome M; Yesil J; Auclair D; Lonial S; Chari A; Cho HJ; Barlogie B; Jagannath S; Dudley JT; Parekh S
Leukemia; 2018 Jan; 32(1):120-130. PubMed ID: 28642592
[TBL] [Abstract][Full Text] [Related]
60. Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level.
John L; Poos AM; Brobeil A; Schinke C; Huhn S; Prokoph N; Lutz R; Wagner B; Zangari M; Tirier SM; Mallm JP; Schumacher S; Vonficht D; Solé-Boldo L; Quick S; Steiger S; Przybilla MJ; Bauer K; Baumann A; Hemmer S; Rehnitz C; Lückerath C; Sachpekidis C; Mechtersheimer G; Haberkorn U; Dimitrakopoulou-Strauss A; Reichert P; Barlogie B; Müller-Tidow C; Goldschmidt H; Hillengass J; Rasche L; Haas SF; van Rhee F; Rippe K; Raab MS; Sauer S; Weinhold N
Nat Commun; 2023 Aug; 14(1):5011. PubMed ID: 37591845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
